Lantheus Holdings, Inc. (NASDAQ:LNTH - Get Free Report) CAO Andrea Sabens sold 341 shares of the firm's stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $61.24, for a total transaction of $20,882.84. Following the transaction, the chief accounting officer now owns 63,239 shares of the company's stock, valued at $3,872,756.36. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Andrea Sabens also recently made the following trade(s):
- On Tuesday, February 13th, Andrea Sabens sold 341 shares of Lantheus stock. The shares were sold at an average price of $55.31, for a total transaction of $18,860.71.
Lantheus Price Performance
Lantheus stock opened at $61.48 on Thursday. Lantheus Holdings, Inc. has a 1 year low of $50.20 and a 1 year high of $100.85. The firm has a 50 day moving average price of $60.52 and a 200 day moving average price of $63.00. The company has a market cap of $4.21 billion, a price-to-earnings ratio of 13.25 and a beta of 0.53. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80.
#1 election stock
From Porter & Company | Ad
I’ve found the number one company to buy…
Before either Trump or Biden wins in November.
It all has to do with an overlooked executive order that Trump signed just days before leaving office… and that Biden has quietly hijacked for his own political power.
For the full story, click here.
Lantheus (NASDAQ:LNTH - Get Free Report) last released its earnings results on Thursday, February 22nd. The medical equipment provider reported $1.59 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.33 by $0.26. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. The firm had revenue of $354.00 million during the quarter, compared to the consensus estimate of $350.44 million. Sell-side analysts predict that Lantheus Holdings, Inc. will post 5.72 earnings per share for the current year.
Institutional Investors Weigh In On Lantheus
Several institutional investors have recently bought and sold shares of LNTH. Tucker Asset Management LLC lifted its position in shares of Lantheus by 239.0% during the third quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider's stock worth $28,000 after purchasing an additional 282 shares in the last quarter. Parkside Financial Bank & Trust lifted its position in shares of Lantheus by 60.2% during the second quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider's stock worth $36,000 after purchasing an additional 160 shares in the last quarter. First Horizon Advisors Inc. lifted its position in shares of Lantheus by 97.0% during the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider's stock worth $32,000 after purchasing an additional 225 shares in the last quarter. Principal Securities Inc. acquired a new position in shares of Lantheus during the fourth quarter worth $28,000. Finally, West Tower Group LLC lifted its position in shares of Lantheus by 534.1% during the fourth quarter. West Tower Group LLC now owns 520 shares of the medical equipment provider's stock worth $32,000 after purchasing an additional 438 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.
Analyst Ratings Changes
A number of equities analysts have recently weighed in on LNTH shares. B. Riley cut their price objective on shares of Lantheus from $113.00 to $95.00 and set a "buy" rating for the company in a research report on Wednesday, January 10th. JMP Securities reissued a "market outperform" rating and issued a $100.00 price objective on shares of Lantheus in a research report on Friday, February 23rd. Truist Financial reissued a "buy" rating and issued a $82.00 price objective (up previously from $80.00) on shares of Lantheus in a research report on Monday, February 26th. Finally, StockNews.com raised shares of Lantheus from a "hold" rating to a "buy" rating in a research report on Saturday, January 13th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average price target of $104.14.
View Our Latest Stock Report on Lantheus
Lantheus Company Profile
(
Get Free Report)
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
